ClinicalTrials.gg
RecruitingNCT07864194Updated Oct 7, 2026

Direct In-Scope Suction Versus Standard Flexible Ureterorenoscopy

An interventional study of Standard flexible ureterorenoscope and Flexible ureterorenoscope with direct in-scope suction in Renal Stone Disease, sponsored by Hitit University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Hitit University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Kidney Calculi with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Kidney Calculi · Turkey.

Planned enrollment
25th of 35
70 · median 90
Started
2026
with 13 others
No phase
32 of 48
15 open now
Primary completion
2026-10
later than 10 of 21 live
Registered
45th of 48
by date
Lead sponsor
5 of 48
Hitit University

Among the 48 studies in Kidney Calculi with a site in Turkey, this one is the 25th largest by planned enrollment of the 35 interventional ones that give a count, is one of 14 that started in 2026, is one of 32 with no phase, reaches primary completion later than 10 of the 21 other live ones, and was the 45th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

21 of the 48 studies in Kidney Calculi with a site in Turkey are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Kidney Calculi with a site in Turkey, or all of them as a file.
02

Study summary

This prospective study aims to compare the clinical, perioperative, and postoperative outcomes of flexible ureterorenoscopy using a direct in-scope suction system (DISS) with standard flexible ureterorenoscopy in patients undergoing retrograde intrarenal surgery for renal or proximal ureteral stones. A total of 70 patients will be enrolled, with 35 patients in each group. The study will assess postoperative infectious complications, including fever, systemic inflammatory response syndrome (SIRS), and sepsis, as well as operative parameters, length of hospital stay, reoperation, and stone-free status. Stone-free status will be assessed by non-contrast computed tomography four weeks after surgery.

Read the detailed description

Retrograde intrarenal surgery (RIRS) is used to treat renal and proximal ureteral stones. During flexible ureterorenoscopy, stone fragments and irrigation fluid may impair visualization, and elevated intrarenal pressure may contribute to postoperative infectious complications. Direct in-scope suction (DISS) permits aspiration through the ureterorenoscope during irrigation and lithotripsy. This study will compare procedural and postoperative outcomes with and without DISS.

This single-center, prospective, randomized, parallel-group study will enroll 70 adults undergoing RIRS at Erol Olçok Training and Research Hospital. Participants will be assigned in a 1:1 ratio to standard flexible ureterorenoscopy or DISS-equipped flexible ureterorenoscopy using a computer-generated randomization sequence. Each group will include 35 participants. Clinical data will be collected during surgery and postoperative follow-up.

The standard group will undergo surgery using a 7.5 Fr Storz Flex-X2 flexible ureterorenoscope. The DISS group will undergo surgery using a 7.5 Fr single-use Claritron flexible ureterorenoscope with direct in-scope suction. Both groups will use a 9.5/11.5 Fr ureteral access sheath, guidewire, Holmium:YAG laser lithotripsy, and normal saline irrigation. Procedures will be performed under general anesthesia in the lithotomy position, with the irrigation bag positioned approximately 100 cm above the patient.

Eligible patients will be aged 18 years or older and undergo RIRS by the same surgical team for a single renal or proximal ureteral stone. Patients with multiple stones, pregnancy, preoperative urinary tract infection, or bleeding diathesis will be excluded.

Demographic and stone characteristics, operative time, fluoroscopy time, total laser energy, length of hospital stay, and need for reoperation will be recorded. Laboratory results, including white blood cell count, C-reactive protein, and creatinine, as well as urine and blood culture results when obtained, will be collected during follow-up.

The primary outcomes are postoperative fever, systemic inflammatory response syndrome (SIRS), and sepsis. Fever is defined as a body temperature >38°C within 48 hours after surgery. SIRS is defined as the presence of at least two of the following: temperature >38°C or \<36°C, heart rate >90 beats/min, respiratory rate >20 breaths/min, or white blood cell count >12,000/mm³ or \<4,000/mm³. For this protocol, sepsis is defined as SIRS with suspected or confirmed infection. For patients who develop infectious complications, treatment, intravenous antibiotic use, and intensive care requirements will be recorded.

Secondary outcomes include stone-free status on non-contrast computed tomography approximately four weeks after surgery, postoperative changes in white blood cell count and creatinine, and postoperative culture findings. Residual fragments ≤4 mm will be classified as clinically insignificant for the study's stone-free assessment.

The two groups will be compared using tests appropriate for the distribution and type of each variable. Categorical data will be reported as counts and percentages. A p value \<0.05 will be considered statistically significant.

03

Conditions studied

  • Renal Stone Disease

Keywords

  • Retrograde intrarenal surgery (RIRS)
  • Kidney stone
  • Infectious complications
  • Urinary tract infection
  • Sepsis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • A single stone located in the kidney or proximal ureter.
  • Scheduled to undergo retrograde intrarenal surgery (RIRS) by the study's surgical team.

Exclusion criteria

Exclusion Criteria:

  • Multiple renal or proximal ureteral stones.
  • Age younger than 18 years.
  • Pregnancy.
  • Preoperative urinary tract infection.
  • Bleeding diathesis.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Standard Flexible Ureterorenoscopy

    Participants randomized to this arm will undergo retrograde intrarenal surgery using a 7.5 Fr Storz Flex-X2 flexible ureterorenoscope without direct in-scope suction. A 9.5/11.5 Fr ureteral access sheath, Holmium:YAG laser lithotripsy, and normal saline irrigation will be used.

    Device: Standard flexible ureterorenoscope

  • Experimental
    Direct In-Scope Suction Flexible Ureterorenoscopy

    Participants randomized to this arm will undergo retrograde intrarenal surgery using a 7.5 Fr single-use Claritron flexible ureterorenoscope equipped with direct in-scope suction. A 9.5/11.5 Fr ureteral access sheath, Holmium:YAG laser lithotripsy, and normal saline irrigation will be used.

    Device: Flexible ureterorenoscope with direct in-scope suction

Interventions

  • DeviceStandard flexible ureterorenoscope

    A 7.5 Fr reusable Storz Flex-X2 flexible ureterorenoscope without direct in-scope suction will be used for retrograde intrarenal surgery. Stone fragmentation will be performed with a Holmium:YAG laser through a 9.5/11.5 Fr ureteral access sheath.

  • DeviceFlexible ureterorenoscope with direct in-scope suction

    A 7.5 Fr single-use Claritron flexible ureterorenoscope equipped with direct in-scope suction will be used for retrograde intrarenal surgery. Suction through the scope will be available during irrigation and Holmium:YAG laser lithotripsy. A 9.5/11.5 Fr ureteral access sheath will be used.

06

What researchers measure

Primary outcomes

  1. Incidence of Postoperative Fever

    Number and percentage of participants with a recorded body temperature \>38°C within 48 hours after surgery.

    Time frame: Within 48 hours after surgery

Secondary outcomes

  1. Incidence of Postoperative Systemic Inflammatory Response Syndrome

    Number and percentage of participants meeting at least two of the following criteria: temperature \>38°C or \<36°C, heart rate \>90 beats/min, respiratory rate \>20 breaths/min, or white blood cell count \>12,000/mm³ or \<4,000/mm³.

    Time frame: Within 48 hours after surgery

  2. Incidence of Postoperative Sepsis

    Number and percentage of participants with suspected or confirmed infection who also meet the protocol-defined systemic inflammatory response syndrome criteria.

    Time frame: Within 48 hours after surgery

  3. Stone-Free Rate

    Number and percentage of participants with no residual stone or residual fragments ≤4 mm on non-contrast computed tomography.

    Time frame: 4 weeks after surgery

07

Study locations

1 of 1 sites recruiting
  • Department of Urology, Hitit University Çorum Erol Olçok Training and Research Hospital, Çorum, Türkiye
    Çorum, Çorum 19040, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Patel PU, Uy M, Dauw C, Sui W, Plott J, Roberts WW, Ghani KR. Direct in-scope suction (DISS) ureteroscopy: techniques, outcomes and future directions. BJU Int. 2026 Mar;137 Suppl 3(Suppl 3):S19-S28. doi: 10.1111/bju.16871. Epub 2025 Aug 5. PubMed 40763000 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 3 months after the start.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 3 months is below that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 7, 2026
StartActual
Jul 7, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Nov 15, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864194
Lead sponsor
Hitit University
Responsible party
Mustafa Serdar CAGLAYAN (Research Assistant Doctor, Hitit University) — Principal investigator
First posted
Oct 7, 2026
Start date
Jul 7, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 15, 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

MUSTAFA SERDAR ÇAĞLAYAN
Contact
serdar.09.09@hotmail.com
+90 507 431 1951
AHMET TAŞCI
Contact
ahmettasci400@gmail.com
+905531596690

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion